Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer
Erythropoietin-producing hepatocellular A2 (EphA2) is a vital member of the Eph tyrosine kinase receptor family and has been associated with developmental processes. However, it is often overexpressed in tumors and correlates with cancer progression and worse prognosis due to the activation of its n...
Gespeichert in:
| Veröffentlicht in: | Journal of molecular medicine (Berlin, Germany) Germany), 2024-04, Vol.102 (4), p.479-493 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 493 |
|---|---|
| container_issue | 4 |
| container_start_page | 479 |
| container_title | Journal of molecular medicine (Berlin, Germany) |
| container_volume | 102 |
| creator | Veiga, Rafaela Nasser de Azevedo, Alexandre Luiz Korte de Oliveira, Jaqueline Carvalho Gradia, Daniela Fiori |
| description | Erythropoietin-producing hepatocellular A2 (EphA2) is a vital member of the Eph tyrosine kinase receptor family and has been associated with developmental processes. However, it is often overexpressed in tumors and correlates with cancer progression and worse prognosis due to the activation of its noncanonical signaling pathway. Throughout cancer treatment, the emergence of drug-resistant tumor cells is relatively common. Since the early 2000s, researchers have focused on understanding the role of EphA2 in promoting drug resistance in different types of cancer, as well as finding efficient and secure EphA2 inhibitors. In this review, the current knowledge regarding induced resistance by EphA2 in cancer treatment is summarized, and the types of cancer that lead to the most cancer-related deaths are highlighted. Some EphA2 inhibitors were also investigated. Regardless of whether the cancer treatment has reached a drug-resistance stage in EphA2-overexpressing tumors, once EphA2 is involved in cancer progression and aggressiveness, targeting EphA2 is a promising therapeutic strategy, especially in combination with other target-drugs for synergistic effect. For that reason, monoclonal antibodies against EphA2 and inhibitors of this receptor should be investigated for efficacy and drug toxicity. |
| doi_str_mv | 10.1007/s00109-024-02431-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2985794760</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2983465476</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-cf452b70630519dba98ed46ca4424987382a12100e2721d148705614bf7dc1c03</originalsourceid><addsrcrecordid>eNp9kMtOwzAQRS0EoqXwAyyQJTZsAn7FjtlVVXlIldiUteU4TpqqSYqdoPbvcUh5iAWLkUfjM3dmLgCXGN1ihMSdRwgjGSHC-qA42h2BMWaURJgxdAzGSDIeEYH5CJx5vw64iCU7BSOaUEk5x2OgltoVti3rAs63qym5hxpuXVOVvi_51unWFnvYNrB5t840lYVmZavGWV_6VtfGQl1nMHNdAX_VyhqaPnHn4CTXG28vDu8EvD7Ml7OnaPHy-DybLiJDCW8jk7OYpAJximIss1TLxGaMG80YYTIRNCEak3C1JYLgDLNEoJhjluYiM9ggOgE3g25Y_q2zvlXhBGM3G13bpvOKyCQWkgneo9d_0HXTuTps11OU8ThggSIDZVzjvbO52rqy0m6vMFK9_WqwXwXr1af9ahearg7SXVrZ7Lvly-8A0AHw4asurPuZ_Y_sBw0Ujz0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2983465476</pqid></control><display><type>article</type><title>Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Veiga, Rafaela Nasser ; de Azevedo, Alexandre Luiz Korte ; de Oliveira, Jaqueline Carvalho ; Gradia, Daniela Fiori</creator><creatorcontrib>Veiga, Rafaela Nasser ; de Azevedo, Alexandre Luiz Korte ; de Oliveira, Jaqueline Carvalho ; Gradia, Daniela Fiori</creatorcontrib><description>Erythropoietin-producing hepatocellular A2 (EphA2) is a vital member of the Eph tyrosine kinase receptor family and has been associated with developmental processes. However, it is often overexpressed in tumors and correlates with cancer progression and worse prognosis due to the activation of its noncanonical signaling pathway. Throughout cancer treatment, the emergence of drug-resistant tumor cells is relatively common. Since the early 2000s, researchers have focused on understanding the role of EphA2 in promoting drug resistance in different types of cancer, as well as finding efficient and secure EphA2 inhibitors. In this review, the current knowledge regarding induced resistance by EphA2 in cancer treatment is summarized, and the types of cancer that lead to the most cancer-related deaths are highlighted. Some EphA2 inhibitors were also investigated. Regardless of whether the cancer treatment has reached a drug-resistance stage in EphA2-overexpressing tumors, once EphA2 is involved in cancer progression and aggressiveness, targeting EphA2 is a promising therapeutic strategy, especially in combination with other target-drugs for synergistic effect. For that reason, monoclonal antibodies against EphA2 and inhibitors of this receptor should be investigated for efficacy and drug toxicity.</description><identifier>ISSN: 0946-2716</identifier><identifier>EISSN: 1432-1440</identifier><identifier>DOI: 10.1007/s00109-024-02431-x</identifier><identifier>PMID: 38393661</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Antibodies, Monoclonal - pharmacology ; Biomedical and Life Sciences ; Biomedicine ; Cancer therapies ; Cell Line, Tumor ; Chemoresistance ; Drug resistance ; Drug Resistance, Neoplasm ; EphA2 protein ; Erythropoietin ; Human Genetics ; Humans ; Internal Medicine ; Medical research ; Molecular Medicine ; Monoclonal antibodies ; Neoplasms - drug therapy ; Neoplasms - metabolism ; Protein-tyrosine kinase receptors ; Receptor, EphA2 - metabolism ; Review ; Signal Transduction ; Toxicity ; Tumor cells ; Tumors</subject><ispartof>Journal of molecular medicine (Berlin, Germany), 2024-04, Vol.102 (4), p.479-493</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c326t-cf452b70630519dba98ed46ca4424987382a12100e2721d148705614bf7dc1c03</cites><orcidid>0000-0002-1452-5807</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00109-024-02431-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00109-024-02431-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38393661$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Veiga, Rafaela Nasser</creatorcontrib><creatorcontrib>de Azevedo, Alexandre Luiz Korte</creatorcontrib><creatorcontrib>de Oliveira, Jaqueline Carvalho</creatorcontrib><creatorcontrib>Gradia, Daniela Fiori</creatorcontrib><title>Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer</title><title>Journal of molecular medicine (Berlin, Germany)</title><addtitle>J Mol Med</addtitle><addtitle>J Mol Med (Berl)</addtitle><description>Erythropoietin-producing hepatocellular A2 (EphA2) is a vital member of the Eph tyrosine kinase receptor family and has been associated with developmental processes. However, it is often overexpressed in tumors and correlates with cancer progression and worse prognosis due to the activation of its noncanonical signaling pathway. Throughout cancer treatment, the emergence of drug-resistant tumor cells is relatively common. Since the early 2000s, researchers have focused on understanding the role of EphA2 in promoting drug resistance in different types of cancer, as well as finding efficient and secure EphA2 inhibitors. In this review, the current knowledge regarding induced resistance by EphA2 in cancer treatment is summarized, and the types of cancer that lead to the most cancer-related deaths are highlighted. Some EphA2 inhibitors were also investigated. Regardless of whether the cancer treatment has reached a drug-resistance stage in EphA2-overexpressing tumors, once EphA2 is involved in cancer progression and aggressiveness, targeting EphA2 is a promising therapeutic strategy, especially in combination with other target-drugs for synergistic effect. For that reason, monoclonal antibodies against EphA2 and inhibitors of this receptor should be investigated for efficacy and drug toxicity.</description><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer therapies</subject><subject>Cell Line, Tumor</subject><subject>Chemoresistance</subject><subject>Drug resistance</subject><subject>Drug Resistance, Neoplasm</subject><subject>EphA2 protein</subject><subject>Erythropoietin</subject><subject>Human Genetics</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Medical research</subject><subject>Molecular Medicine</subject><subject>Monoclonal antibodies</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - metabolism</subject><subject>Protein-tyrosine kinase receptors</subject><subject>Receptor, EphA2 - metabolism</subject><subject>Review</subject><subject>Signal Transduction</subject><subject>Toxicity</subject><subject>Tumor cells</subject><subject>Tumors</subject><issn>0946-2716</issn><issn>1432-1440</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtOwzAQRS0EoqXwAyyQJTZsAn7FjtlVVXlIldiUteU4TpqqSYqdoPbvcUh5iAWLkUfjM3dmLgCXGN1ihMSdRwgjGSHC-qA42h2BMWaURJgxdAzGSDIeEYH5CJx5vw64iCU7BSOaUEk5x2OgltoVti3rAs63qym5hxpuXVOVvi_51unWFnvYNrB5t840lYVmZavGWV_6VtfGQl1nMHNdAX_VyhqaPnHn4CTXG28vDu8EvD7Ml7OnaPHy-DybLiJDCW8jk7OYpAJximIss1TLxGaMG80YYTIRNCEak3C1JYLgDLNEoJhjluYiM9ggOgE3g25Y_q2zvlXhBGM3G13bpvOKyCQWkgneo9d_0HXTuTps11OU8ThggSIDZVzjvbO52rqy0m6vMFK9_WqwXwXr1af9ahearg7SXVrZ7Lvly-8A0AHw4asurPuZ_Y_sBw0Ujz0</recordid><startdate>20240401</startdate><enddate>20240401</enddate><creator>Veiga, Rafaela Nasser</creator><creator>de Azevedo, Alexandre Luiz Korte</creator><creator>de Oliveira, Jaqueline Carvalho</creator><creator>Gradia, Daniela Fiori</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1452-5807</orcidid></search><sort><creationdate>20240401</creationdate><title>Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer</title><author>Veiga, Rafaela Nasser ; de Azevedo, Alexandre Luiz Korte ; de Oliveira, Jaqueline Carvalho ; Gradia, Daniela Fiori</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-cf452b70630519dba98ed46ca4424987382a12100e2721d148705614bf7dc1c03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer therapies</topic><topic>Cell Line, Tumor</topic><topic>Chemoresistance</topic><topic>Drug resistance</topic><topic>Drug Resistance, Neoplasm</topic><topic>EphA2 protein</topic><topic>Erythropoietin</topic><topic>Human Genetics</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Medical research</topic><topic>Molecular Medicine</topic><topic>Monoclonal antibodies</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - metabolism</topic><topic>Protein-tyrosine kinase receptors</topic><topic>Receptor, EphA2 - metabolism</topic><topic>Review</topic><topic>Signal Transduction</topic><topic>Toxicity</topic><topic>Tumor cells</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Veiga, Rafaela Nasser</creatorcontrib><creatorcontrib>de Azevedo, Alexandre Luiz Korte</creatorcontrib><creatorcontrib>de Oliveira, Jaqueline Carvalho</creatorcontrib><creatorcontrib>Gradia, Daniela Fiori</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of molecular medicine (Berlin, Germany)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Veiga, Rafaela Nasser</au><au>de Azevedo, Alexandre Luiz Korte</au><au>de Oliveira, Jaqueline Carvalho</au><au>Gradia, Daniela Fiori</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer</atitle><jtitle>Journal of molecular medicine (Berlin, Germany)</jtitle><stitle>J Mol Med</stitle><addtitle>J Mol Med (Berl)</addtitle><date>2024-04-01</date><risdate>2024</risdate><volume>102</volume><issue>4</issue><spage>479</spage><epage>493</epage><pages>479-493</pages><issn>0946-2716</issn><eissn>1432-1440</eissn><abstract>Erythropoietin-producing hepatocellular A2 (EphA2) is a vital member of the Eph tyrosine kinase receptor family and has been associated with developmental processes. However, it is often overexpressed in tumors and correlates with cancer progression and worse prognosis due to the activation of its noncanonical signaling pathway. Throughout cancer treatment, the emergence of drug-resistant tumor cells is relatively common. Since the early 2000s, researchers have focused on understanding the role of EphA2 in promoting drug resistance in different types of cancer, as well as finding efficient and secure EphA2 inhibitors. In this review, the current knowledge regarding induced resistance by EphA2 in cancer treatment is summarized, and the types of cancer that lead to the most cancer-related deaths are highlighted. Some EphA2 inhibitors were also investigated. Regardless of whether the cancer treatment has reached a drug-resistance stage in EphA2-overexpressing tumors, once EphA2 is involved in cancer progression and aggressiveness, targeting EphA2 is a promising therapeutic strategy, especially in combination with other target-drugs for synergistic effect. For that reason, monoclonal antibodies against EphA2 and inhibitors of this receptor should be investigated for efficacy and drug toxicity.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>38393661</pmid><doi>10.1007/s00109-024-02431-x</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-1452-5807</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0946-2716 |
| ispartof | Journal of molecular medicine (Berlin, Germany), 2024-04, Vol.102 (4), p.479-493 |
| issn | 0946-2716 1432-1440 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2985794760 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Antibodies, Monoclonal - pharmacology Biomedical and Life Sciences Biomedicine Cancer therapies Cell Line, Tumor Chemoresistance Drug resistance Drug Resistance, Neoplasm EphA2 protein Erythropoietin Human Genetics Humans Internal Medicine Medical research Molecular Medicine Monoclonal antibodies Neoplasms - drug therapy Neoplasms - metabolism Protein-tyrosine kinase receptors Receptor, EphA2 - metabolism Review Signal Transduction Toxicity Tumor cells Tumors |
| title | Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T05%3A18%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeting%20EphA2:%20a%20promising%20strategy%20to%20overcome%20chemoresistance%20and%20drug%20resistance%20in%20cancer&rft.jtitle=Journal%20of%20molecular%20medicine%20(Berlin,%20Germany)&rft.au=Veiga,%20Rafaela%20Nasser&rft.date=2024-04-01&rft.volume=102&rft.issue=4&rft.spage=479&rft.epage=493&rft.pages=479-493&rft.issn=0946-2716&rft.eissn=1432-1440&rft_id=info:doi/10.1007/s00109-024-02431-x&rft_dat=%3Cproquest_cross%3E2983465476%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2983465476&rft_id=info:pmid/38393661&rfr_iscdi=true |